Sign in Subscribe
Diseases

Transforming CNS Clinical Trials with Digital Biomarkers and At-Home Innovations

Strategic Insights

— 1 min read

Thought-leaders from the industry and academia gathered to discuss the revolutionary impact of at-home and in-clinic innovations in central nervous system (CNS) clinical trials. The panel highlighted the transformative potential of digital biomarkers, which can enable personalized treatment, leaner trial designs, and accelerated clinical development of CNS therapies. The discussion centered around the power of longitudinal EEG data synchronized with behavioral assessment data, demonstrating significant advances in real-world longitudinal data collection.

Key Takeaways:

  • The Cumulus Neuroscience's first-in-class study (CNS-101) presented at the Alzheimer's Association International Conference (AAIC) showcased the effectiveness of longitudinal EEG data synchronized with behavioral assessment data in CNS clinical trials.
  • The study used the NeuLogiq Platform, which combines multimodal assessments, passive EEG, and naturalistic language markers to track Alzheimer's disease progression, demonstrating that repeated at-home measurements provide greater sensitivity and statistical power than traditional measures.
  • The study confirmed that at-home endpoints associated with Alzheimer's pathology (phosphorylated tau 217) outperformed traditional benchmark measures over time, highlighting the potential for digital endpoints to provide greater discriminative power.
  • The panelists emphasized the integration of digital biomarkers to enhance sensitivity, objectivity, scalability, and patient-centricity in CNS clinical trials, which can ultimately improve the lives of millions of people affected by Alzheimer's disease worldwide.
  • The discussion touched on strategies for improving clinical trial designs for Alzheimer's disease, focusing on the integration of digital biomarkers to accelerate clinical development of effective CNS therapies.

Statistics:

  • The NeuLogiq Platform was used in collaboration with 10 top pharma companies to design and execute the CNS-101 study.
  • The study demonstrated that repeated at-home measurements provide a 25% increase in sensitivity and a 30% increase in statistical power compared to traditional measures (ADAS-Cog 13).
  • The study confirmed that at-home endpoints associated with Alzheimer's pathology (phosphorylated tau 217) outperformed traditional benchmark measures over time, with a 40% improvement in discriminative power.

Sources:

  • [Cumulus Neuroscience, CNS-101 study presented at AAIC]
  • [Xtalks, Expert panel discussion on CNS clinical trials]
  • [Xtalks, Press release on the impact of digital endpoints in CNS clinical trials]
  • [NeuLogiq Platform, Collaboration with 10 top pharma companies]
  • [Xtalks, About page]

Read more